Skip to main content

OTLK

Stock
Health Care
Biotechnology

Performance overview

OTLK Price
Price Chart

Forward-looking statistics

Beta
1.07
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Company info

SectorHealth Care
IndustryBiotechnology
Employees21
Market cap$158.9M

Fundamentals

Enterprise value—
Revenue—
Revenue per employee—
Profit margin—
Debt to equity—

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)—
Avg trading volume (10 day)—
Put-call ratio—

Macro factor sensitivity

Growth-0.7
Credit+7.3
Liquidity-2.0
Inflation-2.9
Commodities-0.1
Interest Rates-1.0

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio-0.45
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings dayMay 16, 2025
Next dividend day—
Ex. dividend day—

News

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

On Thursday, Outlook Therapeutics, Inc. OTLK completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular degeneration (wet AMD) patients.

Benzinga (January 16, 2025)
OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study

Outlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day NORSE EIGHT study for wet AMD.

Zacks Investment Research (November 28, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free